170 related articles for article (PubMed ID: 36977840)
21. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
[TBL] [Abstract][Full Text] [Related]
22. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
23. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
Fairbairn NG; Orfaniotis G; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
[TBL] [Abstract][Full Text] [Related]
24. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
25. Recurrence after sentinel lymph node biopsy in cutaneous melanoma: a single-center experience in Slovak patients.
Sabol M; Reken V; Sabolova L; Waczulikova I; Donat R; Dyttert D; Chvalny P; Durdik S
Neoplasma; 2019 Jul; 66(4):647-651. PubMed ID: 31058535
[TBL] [Abstract][Full Text] [Related]
26. Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?
Ribero S; Osella-Abate S; Sanlorenzo M; Balagna E; Senetta R; Fierro MT; Macripò G; Macrì L; Sapino A; Quaglino P
Ann Surg Oncol; 2015; 22(6):1967-73. PubMed ID: 25388059
[TBL] [Abstract][Full Text] [Related]
27. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy.
Zapas JL; Coley HC; Beam SL; Brown SD; Jablonski KA; Elias EG
J Am Coll Surg; 2003 Sep; 197(3):403-7. PubMed ID: 12946795
[TBL] [Abstract][Full Text] [Related]
28. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma.
Erman AB; Collar RM; Griffith KA; Lowe L; Sabel MS; Bichakjian CK; Wong SL; McLean SA; Rees RS; Johnson TM; Bradford CR
Cancer; 2012 Feb; 118(4):1040-7. PubMed ID: 21773971
[TBL] [Abstract][Full Text] [Related]
29. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
30. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
31. Is sentinel lymph node biopsy of therapeutic relevance for melanoma?
Möhrle M; Schippert W; Rassner G; Garbe C; Breuninger H
Dermatology; 2004; 209(1):5-13. PubMed ID: 15237261
[TBL] [Abstract][Full Text] [Related]
32. Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma.
van Akkooi ACJ; Schadendorf D; Eggermont AMM
Eur J Cancer; 2023 Mar; 182():163-169. PubMed ID: 36681612
[TBL] [Abstract][Full Text] [Related]
33. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test.
Jarell A; Gastman BR; Dillon LD; Hsueh EC; Podlipnik S; Covington KR; Cook RW; Bailey CN; Quick AP; Martin BJ; Kurley SJ; Goldberg MS; Puig S
J Am Acad Dermatol; 2022 Dec; 87(6):1312-1320. PubMed ID: 35810840
[TBL] [Abstract][Full Text] [Related]
34. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients.
Gutzmer R; Al Ghazal M; Geerlings H; Kapp A
Br J Dermatol; 2005 Dec; 153(6):1137-41. PubMed ID: 16307648
[TBL] [Abstract][Full Text] [Related]
35. Conditional Survival-Based "Abbreviated" Routine Cancer Surveillance for Pathologic Stage IB Melanoma.
Kukar M; Gabriel E; May R; Cho E; Lichtenthal M; Groman A; Skitzki J; Francescutti V; Kane JM
Am Surg; 2017 Nov; 83(11):1256-1262. PubMed ID: 29183528
[TBL] [Abstract][Full Text] [Related]
36. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
Kangas-Dick AW; Greenbaum A; Gall V; Groisberg R; Mehnert J; Chen C; Moore DF; Berger AC; Koshenkov V
Ann Surg Oncol; 2021 Aug; 28(8):4582-4589. PubMed ID: 33486642
[TBL] [Abstract][Full Text] [Related]
38. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
[TBL] [Abstract][Full Text] [Related]
39. Sentinel node biopsy status is strongly predictive of survival in cutaneous melanoma: Extended follow-up of Oxford patients from 1998 to 2014.
Thomson DR; Rughani MG; Kuo R; Cassell OCS
J Plast Reconstr Aesthet Surg; 2017 Oct; 70(10):1397-1403. PubMed ID: 28625757
[TBL] [Abstract][Full Text] [Related]
40. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW
Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
